Why?
Because CBIS is one of the only companies, and possibly the only U.S. company, seriously investigating the most controversial medicinal properties of phytocannabinoids and working to develop products and getting FDA approval for them. They aren't just taking the easy route and targeting pain, nausea etc... but they're targeting cancer, AIDS, PTSD etc... which could help an enormous amount of people, but also puts pressure on big pharma. This also provides them with a huge market potential alongside the potential for enormous media attention.
It's not just an "election hangover", it's progress being made in the public perception and knowledge of cannabinoids and their beneficial medicinal effects, which seriously increases the chances of obtaining FDA approval and the financial stimuli necessary to conduct clinical trials. Improving legal circumstances and pressure on the DEA, FDA etc... to reassess their stance. It is understandable CBIS has not been able to provide many concrete results or much revenue up till now, looking at the goals they have set, but the chances of getting those results are improving. Find me biotechs of the same age and with the same potential that are generating substantial revenue. I challenge you.
There's no doubt we will reach a peak on momentum that will not be sustainable for long, but I also posit we still have quite a distance to go before we reach that top. And I am confident CBIS will be able to present some very significant achievements later this year or beginning next year.
News 
Market Data 
Discover 
